FLT3 and neoplasm: Therefore, an anti-tumor antibody targeting CD52, such as alemtuzumab, is a potential therapeutic alternative for AML with FLT3-ITD, given that this antibody targets and kills leukemic cells by a mechanism that is different from that of the FLT3 kinase inhibitors.